Long-Term Management: Preventing Progression. Daniel Burkhoff Cardiovascular Research Foundation and Columbia University

Size: px
Start display at page:

Download "Long-Term Management: Preventing Progression. Daniel Burkhoff Cardiovascular Research Foundation and Columbia University"

Transcription

1 Long-Term Management: Preventing Progression Daniel Burkhoff Cardiovascular Research Foundation and Columbia University

2 Disclosure Unrestricted institutional (CRF) educational grant from Abiomed

3 Left Ventricular Pressure Heart Failure Progression Summarized by PV Analysis: LV Remodeling Explained Acute NH Activation Chronic NH Activation, Inflammation Remodeling Normal CHF Left Ventricular Volume

4 Degree of Remodeling Relates to Size of Infarct (3 months follow-up) Pfeffer JM, Pfeffer MA, Braunwald E: Circ Res 1985;57:84

5

6 INFARCT SIZE LV REMODELING HEART FAILURE

7 Vicious Cycle of HFrEF Remodeling Apoptosis Remodeling Hypertrophy Hypertrophy Dilation / MR Dilation / MR Dyssynchrony Dyssynchrony Arrhythmias (+) Maladaptive Myocyte Loss And Weakness Afterload Preload HR Contractility LV Pump Function Adaptive Sympathetic Activation NE Epi DA (-) CO BP Renal Hypoperfusion Renin AngII Aldo Na/H 2 O Retention Cytokines Compensatory Mechanisms (Adaptive / Maladaptive) Stress ANP BNP

8 Preventing/minimizing heart failure and subsequent disease progression: It all comes down to limiting infarct size Better to prevent/minimize remodeling than to try to reverse it

9 Timilol

10 BHAT Study Propranolol

11 Brivet et al

12 Pharmacologic Unloading Attenuates Remodeling Sham Captopril Control Captorpil Reduces Preload (EDP) Pfeffer JM, Pfeffer MA, Braunwald E: Circ Res 1985;57:84

13 The Larger the Infarct, the Less the Prevention of Remodeling Pfeffer JM, Pfeffer MA, Braunwald E: Circ Res 1985;57:84

14 SAVE Pfeffer et al, NEJM 1992

15 Current Guidelines for STEMI Include: B-blockers + ACEi/ARB unless heart failure, hypotension, etc 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction JACC 2013

16 Improved regional myocardial blood flow, left ventricular unloading and infarct salvage using an axial-flow, transvalvular left ventricular assist device: A comparison with intra-aortic balloon counterpulsation and reperfusion alone in a canine infarction model Smalling et al Circulation1992;85: *LV assistance was maintained during the entire period of occlusion and reperfusion

17 Why is unloading so important? Left ventricular unloading by cathetermounted axial flow pump reduces infarct size Meyns et al, JACC 2003;41: Area at risk (AAR) % AAR Infarcted Control (reperfusion alone) Unloading During Isch & Reperfusion Unloading during Reperfusion Partial Unloading during Reperfusion

18 Necroptosis, Apoptosis and Autophagy Play Role in Peri- and Post-infarct Remodeling

19 Mechanical Pre-Conditioning With Acute Circulatory Support Before Reperfusion Limits Infarct Size in Acute Myocardial Infarction Kapur et al. J Am Coll Cardiol HF 2015;3:873 82

20 LV Unloading before reperfusion promotes functional recovery after AMI Esposito, Kapur, et al. JACC 2018

21 Acute Mechanisms and Factors that lead to Remodeling Loss of Myocytes Necroptosis Apoptosis Autophagy Inflammation Collagen breakdown Physical Forces that stretch the infarct zone Increased diastolic wall stress End-diastolic pressure All of these factors and mechanisms are activated at the time of AMI; remodeling begins essentially immediately

22 Preventing/minimizing heart failure and subsequent disease progression: It all comes down to limiting infarct size Better to prevent/minimize remodeling than to try to reverse it

23 AHA/ACC/HFSA Guidelines are all Geared to Preventing Progression

24 LV Reverse Remodeling Therapy Comparisons* Enalapril Carvedilol CRT CONSESUS et al Konstam et al. 1 year Doughty et al Packer et al 1 Year Abraham et al 6 months MV Repair MV Replace Acker et al. N Eng J Med year MITRA-FR 1 year MitraClip COAPT 2 year Δ EF% ? Δ ESV (ml) ml (EDV) Mortality (% risk reductio n) 31% 65% 10% Not Evaluated Not Evaluated No Effect ~40% Death or HF Hosp 50% 27% 18% Not Evaluated Not Evaluated No Effect ~50% *Medical therapies turn back the clock, but remodeling progresses

25 Summary Remodeling starts immediately with AMI The larger the infarct the more the subsequent remodeling Remodeling can be reduced by pharmacologic (bblockers, ACEi/ARBs) and by mechanical unloading The relevant pharmacologic therapies are not applicable in CS Molecular mechanisms underlying necroptosis, apoptosis and autophagy being clarified Molecular impact of mechanical unloading starting to be understood Once remodeling is present, reversal is difficult and disease progression is inevitable Minimizing infarct size is the key to preventing heart failure and minimizing disease progression

26 Impella ASAP RHC to guide therapy

27 Door-to-Unload Study Door To Unload: Kapur, O Neill, STEMI DTU Safety Investigators & Feasibility Trial Anterior STEMI Referred for Primary PCI (WITHOUT SHOCK) ENROLLMENT INCLUSION CRITERIA COMPLETED Age years First Myocardial Infarction May 2018 Acute STEMI (anterior ST elevation 2 mm in 2 contiguous or 4 mm ST-sum) Within 1 to 6 hours of symptom onset LV Unloading, Then Immediate PCI Reperfusion (U-IR Group) Informed Consent Enrollment and Randomization LBCT Presentation at Impella CP Insertion + Activation AHA Scientific Sessions LV Unloading for 30 minutes, Then Delayed Reperfusion (U-DR Group) November Chicago Explant Impella CP after a minimum of 3 hours support

Recovering Hearts. Saving Lives.

Recovering Hearts. Saving Lives. Recovering Hearts. Saving Lives ṬM The Door to Unload (DTU) STEMI Safety & Feasibility Pilot Trial November 218 Recovering Hearts. Saving Lives. LEGAL DISCLAIMERS This presentation includes select slides

More information

Rationale for Prophylactic Support During Percutaneous Coronary Intervention

Rationale for Prophylactic Support During Percutaneous Coronary Intervention Rationale for Prophylactic Support During Percutaneous Coronary Intervention Navin K. Kapur, MD, FACC, FSCAI Assistant Director, Interventional Cardiology Director, Interventional Research Laboratories

More information

The Pathophysiology of Cardiogenic Shock Knowledge Gaps & Opportunities

The Pathophysiology of Cardiogenic Shock Knowledge Gaps & Opportunities The Pathophysiology of Cardiogenic Shock Knowledge Gaps & Opportunities Navin K. Kapur, MD, FACC, FSCAI, FAHA Associate Professor, Department of Medicine Interventional Cardiology & Advanced Heart Failure

More information

Bridging With Percutaneous Devices: Tandem Heart and Impella

Bridging With Percutaneous Devices: Tandem Heart and Impella Bridging With Percutaneous Devices: Tandem Heart and Impella DAVID A. BARAN, MD, FACC, FSCAI SYSTEM DIRECTOR, ADVANCED HEART FAILURE, TX AND MCS SENTARA HEART HOSPITAL NORFOLK, VA PROFESSOR OF MEDICINE

More information

Introduction to Acute Mechanical Circulatory Support

Introduction to Acute Mechanical Circulatory Support Introduction to Acute Mechanical Circulatory Support Navin K. Kapur, MD, FACC, FSCAI, FAHA Associate Professor, Department of Medicine Interventional Cardiology & Advanced Heart Failure Programs Executive

More information

Rationale for Left Ventricular Support During Percutaneous Coronary Intervention

Rationale for Left Ventricular Support During Percutaneous Coronary Intervention Rationale for Left Ventricular Support During Percutaneous Coronary Intervention Navin K. Kapur, MD, FACC, FSCAI Associate Professor, Division of Cardiology Director, Acute Circulatory Support Program

More information

Assist Devices in STEMI- Intra-aortic Balloon Pump

Assist Devices in STEMI- Intra-aortic Balloon Pump Assist Devices in STEMI- Intra-aortic Balloon Pump Ioannis Iakovou, MD, PhD Onassis Cardiac Surgery Center Athens, Greece Cardiogenic shock 5-10% of pts after a heart attack 60000-70000 pts in Europe/year

More information

Acute Myocardial Infarction Complicated by Cardiogenic Shock

Acute Myocardial Infarction Complicated by Cardiogenic Shock Acute Myocardial Infarction Complicated by Cardiogenic Shock Navin K. Kapur, MD, FACC, FSCAI Assistant Professor, Division of Cardiology Director, Acute Circulatory Support Program Director, Interventional

More information

Intraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend )

Intraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend ) Intraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend ) Stephen G. Ellis, MD Section Head, Interventional Cardiology Professor of Medicine Cleveland

More information

Percutaneous Mechanical Circulatory Support Devices

Percutaneous Mechanical Circulatory Support Devices Percutaneous Mechanical Circulatory Support Devices Daniel Vazquez RN, RCIS Miami Cardiac & Vascular Institute FINANCIAL DISCLOSURES none CASE STUDY CASE STUDY 52 year old gentlemen Complaining of dyspnea

More information

Outline. Pathophysiology: Heart Failure. Heart Failure. Heart Failure: Definitions. Etiologies. Etiologies

Outline. Pathophysiology: Heart Failure. Heart Failure. Heart Failure: Definitions. Etiologies. Etiologies Outline Pathophysiology: Mat Maurer, MD Irving Assistant Professor of Medicine Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology : Definitions An inability of the

More information

Mechanics of Cath Lab Support Devices

Mechanics of Cath Lab Support Devices Mechanics of Cath Lab Support Devices Issam D. Moussa, MD Professor of Medicine Mayo Clinic College of Medicine Chair, Division of Cardiovascular Diseases Mayo Clinic Jacksonville, Florida DISCLOSURE Presenter:

More information

Pathophysiology: Heart Failure

Pathophysiology: Heart Failure Pathophysiology: Heart Failure Mat Maurer, MD Irving Assistant Professor of Medicine Outline Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology Heart Failure: Definitions

More information

Matching Patient and Pump in the New Era of Percutaneous Mechanical Circulatory Support

Matching Patient and Pump in the New Era of Percutaneous Mechanical Circulatory Support Matching Patient and Pump in the New Era of Percutaneous Mechanical Circulatory Support Navin K. Kapur, MD, FACC, FSCAI, FAHA Associate Professor, Department of Medicine Interventional Cardiology & Advanced

More information

Mechanics of Cath Lab Support Devices

Mechanics of Cath Lab Support Devices Mechanics of Cath Lab Support Devices Issam D. Moussa, MD Chief Medical Officer First Coast Cardiovascular Institute, Jacksonville, FL Professor of Medicine, UCF, Orlando, FL None DISCLOSURE Percutaneous

More information

A case of post myocardial infarction ventricular septal rupture CHRISTOFOROS KOBOROZOS, MD

A case of post myocardial infarction ventricular septal rupture CHRISTOFOROS KOBOROZOS, MD A case of post myocardial infarction ventricular septal rupture CHRISTOFOROS KOBOROZOS, MD NAVAL HOSPITAL OF ATHENS case presentation Female, 81yo Hx: diabetes mellitus, hypertension, chronic anaemia presented

More information

ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure

ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure - 2005 Karl Swedberg Professor of Medicine Department of Medicine Sahlgrenska University Hospital/Östra Göteborg University Göteborg

More information

IN VIVO ASSESSMENT OF CENTRAL AND PERIPHERAL HEMODYNAMIC IMPACT OF THE C-PULSE SYSTEM

IN VIVO ASSESSMENT OF CENTRAL AND PERIPHERAL HEMODYNAMIC IMPACT OF THE C-PULSE SYSTEM IN VIVO ASSESSMENT OF CENTRAL AND PERIPHERAL HEMODYNAMIC IMPACT OF THE C-PULSE SYSTEM Francisco Javier Londono Hoyos, PhD; Dimitrios Georgakopoulos, PhD; Oliver Fey; Dori Jones, MS; Christian Schlensak,

More information

Mechanical circulatory support in cardiogenic shock The Cardiologist s view ACCA Masterclass 2017

Mechanical circulatory support in cardiogenic shock The Cardiologist s view ACCA Masterclass 2017 Mechanical circulatory support in cardiogenic shock The Cardiologist s view ACCA Masterclass 2017 Pascal Vranckx MD, PhD. Medical director Cardiac Critical Care Services Hartcentrum Hasselt Belgium Disclosure

More information

How to do Primary Angioplasty. - Patients with Cardiogenic Shock

How to do Primary Angioplasty. - Patients with Cardiogenic Shock How to do Primary Angioplasty - Patients with Cardiogenic Shock Advanced Cardiovascular Intervention 2011 Dan Blackman Leeds General Infirmary MY CONFLICTS OF INTEREST ARE: Research Grants Medicines Company

More information

CARDIOGENIC SHOCK. Antonio Pesenti. Università degli Studi di Milano Bicocca Azienda Ospedaliera San Gerardo Monza (MI)

CARDIOGENIC SHOCK. Antonio Pesenti. Università degli Studi di Milano Bicocca Azienda Ospedaliera San Gerardo Monza (MI) CARDIOGENIC SHOCK Antonio Pesenti Università degli Studi di Milano Bicocca Azienda Ospedaliera San Gerardo Monza (MI) Primary myocardial dysfunction resulting in the inability of the heart to mantain an

More information

WHAT S NEW IN HEART FAILURE

WHAT S NEW IN HEART FAILURE WHAT S NEW IN HEART FAILURE Drugs, Devices and Diagnostics John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine Eastern Virginia Medical School

More information

Percutaneous mechanical circulatory support for treatment and prevention of hemodynamic instability Engström, A.E.

Percutaneous mechanical circulatory support for treatment and prevention of hemodynamic instability Engström, A.E. UvA-DARE (Digital Academic Repository) Percutaneous mechanical circulatory support for treatment and prevention of hemodynamic instability Engström, A.E. Link to publication Citation for published version

More information

The Therapeutic Potential of Novel Approaches to RAAS. Professor of Medicine University of California, San Diego

The Therapeutic Potential of Novel Approaches to RAAS. Professor of Medicine University of California, San Diego The Therapeutic Potential of Novel Approaches to RAAS Inhibition in Heart Failure Barry Greenberg, M.D. Professor of Medicine University of California, San Diego Chain of Events Leading to End-Stage Heart

More information

Cardiogenic Shock and Initiatives to Reduce Mortality

Cardiogenic Shock and Initiatives to Reduce Mortality Cardiogenic Shock and Initiatives to Reduce Mortality Tanveer Rab, MD, FACC William O Neill, MD, FACC Perwaiz Meraj, MD, FACC Alex Truesdell, MD, FACC The Golden Hours? 50% dead within 10 hours Overall

More information

Risk Stratification in Heart Failure: The Role of Emerging Biomarkers

Risk Stratification in Heart Failure: The Role of Emerging Biomarkers Risk Stratification in Heart Failure: The Role of Emerging Biomarkers David G. Grenache, PhD Associate Professor of Pathology, University of Utah Medical Director, ARUP Laboratories Salt Lake City, UT

More information

ACE inhibitors: still the gold standard?

ACE inhibitors: still the gold standard? ACE inhibitors: still the gold standard? Session: Twenty-five years after CONSENSUS What have we learnt about the RAAS in heart failure? Lars Køber, MD, D.Sci Department of Cardiology Rigshospitalet University

More information

Pathophysiology: Heart Failure. Objectives

Pathophysiology: Heart Failure. Objectives Pathophysiology: Heart Failure Mat Maurer, MD Irving Assistant Professor of Clinical Medicine Objectives At the conclusion of this seminar, learner will be able to: 1. Define heart failure as a clinical

More information

DISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE

DISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION Lori M. Tam, MD Providence Heart Institute DISCLOSURES NONE 1 OUTLINE Systolic vs. Diastolic Heart Failure New

More information

IABP SHOCK II trial:

IABP SHOCK II trial: IABP SHOCK II trial: Randomized comparison of intraaortic balloon counterpulsation versus optimal medical therapy in addition to early revascularization in acute myocardial infarction complicated by cardiogenic

More information

Cardiogenic Shock. Dr. JPS Henriques. Academic Medical Center University of Amsterdam The Netherlands

Cardiogenic Shock. Dr. JPS Henriques. Academic Medical Center University of Amsterdam The Netherlands Cardiogenic Shock Dr. JPS Henriques Academic Medical Center University of Amsterdam The Netherlands Conflict of interest disclosure Research grant Abbott Vascular Research grant Abiomed Inc. Global Impella

More information

Percutaneous Mechanical Circulatory Support for Cardiogenic Shock. 24 th Annual San Diego Heart Failure Symposium Ryan R Reeves, MD FSCAI

Percutaneous Mechanical Circulatory Support for Cardiogenic Shock. 24 th Annual San Diego Heart Failure Symposium Ryan R Reeves, MD FSCAI Percutaneous Mechanical Circulatory Support for Cardiogenic Shock 24 th Annual San Diego Heart Failure Symposium Ryan R Reeves, MD FSCAI The Need for Circulatory Support Basic Pathophysiologic Problems:

More information

CRT response: definition and handling of non-responders

CRT response: definition and handling of non-responders CRT response: definition and handling of non-responders Maurizio Gasparini Chief of Electrophysiology and Pacing Unit IRCCS, Istituto Clinico Humanitas, Rozzano- Italy Definition of non-responders First

More information

Case - Advanced HF and Shock (INTERMACS 1)

Case - Advanced HF and Shock (INTERMACS 1) Case - Advanced HF and Shock (INTERMACS 1) Navin K. Kapur, MD, FACC, FSCAI, FAHA Associate Professor, Department of Medicine Interventional Cardiology & Advanced Heart Failure Programs Executive Director,

More information

Cardiogenic Shock. Carlos Cafri,, MD

Cardiogenic Shock. Carlos Cafri,, MD Cardiogenic Shock Carlos Cafri,, MD SHOCK= Inadequate Tissue Mechanisms: Perfusion Inadequate oxygen delivery Release of inflammatory mediators Further microvascular changes, compromised blood flow and

More information

DECLARATION OF CONFLICT OF INTEREST

DECLARATION OF CONFLICT OF INTEREST DECLARATION OF CONFLICT OF INTEREST Cardiogenic Shock Mechanical Support Eulàlia Roig FESC Heart Failure and HT Unit Hospital Sant Pau - UAB Barcelona. Spain No conflics of interest Mechanical Circulatory

More information

Ventricular Assisting Devices in the Cathlab. Unrestricted

Ventricular Assisting Devices in the Cathlab. Unrestricted Ventricular Assisting Devices in the Cathlab Unrestricted What is a VAD? A single system device that is surgically attached to the left ventricle of the heart and to the aorta for left ventricular support

More information

Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -

Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology

More information

Heart Failure (HF) Treatment

Heart Failure (HF) Treatment Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and

More information

2018 TCT Investor Update

2018 TCT Investor Update 1 2018 TCT Investor Update September 2018 LEGAL DISCLAIMERS 2 This presentation contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the

More information

Optimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure

Optimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues

More information

Definition of Congestive Heart Failure

Definition of Congestive Heart Failure Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million

More information

The majority of patients with cardiomyopathy

The majority of patients with cardiomyopathy Selection of Hemodynamic Support: An Approach for Coronary Interventions in Shock and High-Risk PCI The role of hemodynamic support devices in emergent cardiogenic shock and elective high-risk percutaneous

More information

PUMP FAILURE COMPLICATING AMI: ISCHAEMIC VSR

PUMP FAILURE COMPLICATING AMI: ISCHAEMIC VSR PUMP FAILURE COMPLICATING AMI: ISCHAEMIC VSR Dr Susanna Price MD PhD MRCP ESICM FFICM FESC Consultant Cardiologist & Intensivist Royal Brompton & Harefield NHS Foundation Trust DECLARATIONS Educational

More information

Mechanical Cardiac Support in Acute Heart Failure. Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research

Mechanical Cardiac Support in Acute Heart Failure. Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research Mechanical Cardiac Support in Acute Heart Failure Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research Disclosures Research Support and/or Consulting NHLBI Amgen Cytokinetics

More information

CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand

CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand ENHANCED EXTERNAL COUNTER PULSATION Piyanuj Ruckpanich, MD. Cardiac Rehabilitation Center Perfect

More information

Aldosterone Antagonism in Heart Failure: Now for all Patients?

Aldosterone Antagonism in Heart Failure: Now for all Patients? Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C

More information

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National

More information

Should All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function?

Should All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function? Should All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function? Avi Shimony, MD, FESC Cardiology Division Soroka University Medical Center Ben-Gurion University, Beer-Sheva Disclosure

More information

Outcomes for 15,259 US Patients With Acute MI Cardiogenic Shock (AMICS) Supported With Impella

Outcomes for 15,259 US Patients With Acute MI Cardiogenic Shock (AMICS) Supported With Impella Outcomes for 15,259 US Patients With Acute MI Cardiogenic Shock (AMICS) Supported With Impella William O Neill, MD, FACC Medical Director Structural Heart Disease at Henry Ford Hospital, MI AMI Shock Mortality

More information

Pathophysiology: Heart Failure. Objectives

Pathophysiology: Heart Failure. Objectives Pathophysiology: Heart Failure Mat Maurer, MD Associate Professor of Clinical Medicine Objectives At the conclusion of this seminar, learners will be able to: 1. Define heart failure as a clinical syndrome

More information

CNR, G. Monasterio Foundation, Clinical Physiology Institute Pisa

CNR, G. Monasterio Foundation, Clinical Physiology Institute Pisa CNR, G. Monasterio Foundation, Clinical Physiology Institute Pisa Stockholm Aug 29, 2010 Role of MRI in the acute Myocardial Infarction? massimo lombardi Two days after infarct (top row), the T2 hyperintense

More information

ST-Elevation Myocardial Infarction & Cardiogenic Shock. - What Should We Do?

ST-Elevation Myocardial Infarction & Cardiogenic Shock. - What Should We Do? ST-Elevation Myocardial Infarction & Cardiogenic Shock - What Should We Do? Advanced Angioplasty 2008 Dan Blackman Leeds General Infirmary Conflicts of interest Advisory Boards Cordis Boston Scientific

More information

The Role of ICD Therapy in Cardiac Resynchronization

The Role of ICD Therapy in Cardiac Resynchronization The Role of ICD Therapy in Cardiac Resynchronization The Korean Society of Circulation 15 April 2005 Angel R. León, MD Carlyle Fraser Heart Center Division of Cardiology Emory University School of Medicine

More information

Ray Matthews MD Professor of Clinical Medicine Chief of Cardiology University of Southern California

Ray Matthews MD Professor of Clinical Medicine Chief of Cardiology University of Southern California High Risk PCI Making Possible the Impossible Ray Matthews MD Professor of Clinical Medicine Chief of Cardiology University of Southern California Disclosures Abiomed Research Support Consulting Agreement

More information

Management of Cardiogenic shock. Prof. Christian JM Vrints

Management of Cardiogenic shock. Prof. Christian JM Vrints Management of Cardiogenic shock Prof. Christian JM Vrints none conflicts Management of Cardiogenic Shock Incidence and trends Importance of early revascularization Multivessel disease Left main disease

More information

CKD Satellite Symposium

CKD Satellite Symposium CKD Satellite Symposium Recommended Therapy by Heart Failure Stage AHA/ACC Task Force on Practice Guideline 2001 Natural History of Heart Failure Patients surviving % Mechanism of death Sudden death 40%

More information

Cath Lab Essentials : LV Assist Devices for Hemodynamic Support (IABP, Impella, Tandem Heart, ECMO)

Cath Lab Essentials : LV Assist Devices for Hemodynamic Support (IABP, Impella, Tandem Heart, ECMO) Cath Lab Essentials : LV Assist Devices for Hemodynamic Support (IABP, Impella, Tandem Heart, ECMO) Michael A. Gibson, MD Assistant Professor of Medicine University of California, Irvine Division of Cardiology

More information

Influence of Location and Size of Myocardial Infarction on Post-infarction Remodelling

Influence of Location and Size of Myocardial Infarction on Post-infarction Remodelling Influence of Location and Size of Myocardial Infarction on Post-infarction Remodelling Masci PG, MD ; Ganame J, MD ; Francone M, MD, PhD # ; Desmet W, MD ; Iacucci I, MD # ; Barison A, MD ; Carbone I,

More information

A National Cardiogenic Shock Initiative (CSI):

A National Cardiogenic Shock Initiative (CSI): A National Cardiogenic Shock Initiative (CSI): Insights from the Impella Quality (IQ) Program, cvad Registry and the Detroit CSI Experience William O Neill, MD, FACC Medical Director Structural Heart Disease

More information

STEMI Stents What next? Arshad Khan - HNE Clinical Research Fellow. Supervisors: Prof Boyle and Attia.

STEMI Stents What next? Arshad Khan - HNE Clinical Research Fellow. Supervisors: Prof Boyle and Attia. STEMI Stents What next? Arshad Khan - HNE Clinical Research Fellow. Supervisors: Prof Boyle and Attia. PART 1 Systems of care for STEMI. STEMI Management Coronary angiogram +/- stenting. Prehospital thrombolysis

More information

Disclosure Statement. Heart Failure: Refreshers and Updates. Objectives. CHF: Chronic Heart Failure. Definitions. Definitions 2/19/2018

Disclosure Statement. Heart Failure: Refreshers and Updates. Objectives. CHF: Chronic Heart Failure. Definitions. Definitions 2/19/2018 Disclosure Statement Heart Failure: Refreshers and Updates Tracy K. Pettinger, PharmD Clinical Associate Professor College of Pharmacy The planners and presenter of this presentation have disclosed no

More information

4/22/2016 Updated. AllinaHealthSystem. Cardiogenic Shock: Definition. No Disclosures. Cardiogenic Shock: Declining (But Still High) Case Fatality Rate

4/22/2016 Updated. AllinaHealthSystem. Cardiogenic Shock: Definition. No Disclosures. Cardiogenic Shock: Declining (But Still High) Case Fatality Rate 4/22/216 Updated Definition End-organ hypoperfusion secondary to cardiac failure Advanced Cardiopulmonary Support for the Critically Ill Adult April 22, 216 Cardiogenic Shock Michael A. Samara, MD FACC

More information

Rational use of imaging for viability evaluation

Rational use of imaging for viability evaluation EUROECHO and other imaging modalities 2011 Rational use of imaging for viability evaluation Luc A. Pierard, MD, PhD, FESC, FACC Professor of Medicine Head, Department of Cardiology, CHU Liège, Belgium

More information

PHARMACOLOGICAL MANAGEMENT OF CARDIOGENIC SHOCK

PHARMACOLOGICAL MANAGEMENT OF CARDIOGENIC SHOCK PHARMACOLOGICAL MANAGEMENT OF CARDIOGENIC SHOCK Doron Zahger, MD Department of Cardiology, Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva,

More information

Disclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017

Disclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies

More information

Low cardiac output & Mechanical Support นายแพทย อรรถภ ม ส ศ ภอรรถ ศ ลยศาสตร ห วใจและทรวงอก โรงพยาบาล ราชว ถ

Low cardiac output & Mechanical Support นายแพทย อรรถภ ม ส ศ ภอรรถ ศ ลยศาสตร ห วใจและทรวงอก โรงพยาบาล ราชว ถ Low cardiac output & Mechanical Support นายแพทย อรรถภ ม ส ศ ภอรรถ ศ ลยศาสตร ห วใจและทรวงอก โรงพยาบาล ราชว ถ Low cardiac output/cardiogenic Shock State of end-organ hypoperfusion due to cardiac failure.

More information

Heart Failure. Cardiac Anatomy. Functions of the Heart. Cardiac Cycle/Hemodynamics. Determinants of Cardiac Output. Cardiac Output

Heart Failure. Cardiac Anatomy. Functions of the Heart. Cardiac Cycle/Hemodynamics. Determinants of Cardiac Output. Cardiac Output Cardiac Anatomy Heart Failure Professor Qing ZHANG Department of Cardiology, West China Hospital www.blaufuss.org Cardiac Cycle/Hemodynamics Functions of the Heart Essential functions of the heart to cover

More information

Joo-Yong Hahn, MD/PhD

Joo-Yong Hahn, MD/PhD Sungkyunkwan University School of Medicine Joo-Yong Hahn, MD/PhD Heart Vascular Stork Institute, Samsung Medical Center Sungkyunkwan University School of Medicine Grant support Korean Society of Interventional

More information

Innovation therapy in Heart Failure

Innovation therapy in Heart Failure Innovation therapy in Heart Failure P. Laothavorn September 2015 Topics of discussion Basic Knowledge about heart failure Standard therapy New emerging therapy References: standard Therapy in Heart Failure

More information

Intravenous Inotropic Support an Overview

Intravenous Inotropic Support an Overview Intravenous Inotropic Support an Overview Shaul Atar, MD Western Galilee Medical Center, Nahariya Affiliated with the Faculty of Medicine of the Galilee, Safed, Israel INOTROPES in Acute HF (not vasopressors)

More information

Acute myocardial infarction (AMI) remains a

Acute myocardial infarction (AMI) remains a JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 72, NO. 5, 218 ª 218 PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION JACC REVIEW TOPIC OF THE WEEK Mechanical Unloading

More information

Prognostic Value of Intramyocardial Hemorrhage Detected by Cardiac Magnetic Resonance Imaging in Acute Reperfused ST-Elevation Myocardial Infarction

Prognostic Value of Intramyocardial Hemorrhage Detected by Cardiac Magnetic Resonance Imaging in Acute Reperfused ST-Elevation Myocardial Infarction Prognostic Value of Intramyocardial Hemorrhage Detected by Cardiac Magnetic Resonance Imaging in Acute Reperfused ST-Elevation Myocardial Infarction Holger Thiele, MD; Konrad Kubusch, BSc; Steffen Desch,

More information

1. LV function and remodeling. 2. Contribution of myocardial ischemia due to CAD, and

1. LV function and remodeling. 2. Contribution of myocardial ischemia due to CAD, and 1 The clinical syndrome of heart failure in adults is commonly associated with the etiologies of ischemic and non-ischemic dilated cardiomyopathy, hypertrophic cardiomyopathy, hypertensive heart disease,

More information

LXIV: DRUGS: 4. RAS BLOCKADE

LXIV: DRUGS: 4. RAS BLOCKADE LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations

More information

Advanced Care for Decompensated Heart Failure

Advanced Care for Decompensated Heart Failure Advanced Care for Decompensated Heart Failure Sara Kalantari MD Assistant Professor of Medicine, University of Chicago Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation

More information

Ted Feldman, M.D., MSCAI FACC FESC

Ted Feldman, M.D., MSCAI FACC FESC Support Technologies and High Risk Intervention Patient Selection: When Not to Use Them Ted Feldman, M.D., MSCAI FACC FESC Evanston Hospital SCAI Fall Fellows Course Las Vegas December 7-10 th, 2014 Ted

More information

TREATMENT OF HIGHER RISK PATIENTS INTRODUCTION TO PROTECTED PCI WITH IMPELLA. IMP v4

TREATMENT OF HIGHER RISK PATIENTS INTRODUCTION TO PROTECTED PCI WITH IMPELLA. IMP v4 1 TREATMENT OF HIGHER RISK PATIENTS INTRODUCTION TO PROTECTED PCI WITH IMPELLA FDA APPROVES IMPELLA FOR HIGH-RISK PCI 2 Impella is the only hemodynamic support device proven safe and effective in elective

More information

Latest therapies for patients with HF. Dr AIGUL BALTABAEVA PhD, FESC, FRCP RBHT & ASPH

Latest therapies for patients with HF. Dr AIGUL BALTABAEVA PhD, FESC, FRCP RBHT & ASPH Latest therapies for patients with HF Dr AIGUL BALTABAEVA PhD, FESC, FRCP RBHT & ASPH ESC HF Guidelines 2016 ESC HF Guidelines 2016: Pharmacological Treatments Pathways blocked by ACE-I, ARB and NI Effect

More information

Heart Failure Therapies State of the Art 2017

Heart Failure Therapies State of the Art 2017 Heart Failure Therapies State of the Art 2017 Andrew J. Sauer, MD Assistant Professor Director, Center for Heart Failure Medical Director, Heart Transplantation UNOS Primary Transplant Physician asauer@kumc.edu

More information

Cardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center

Cardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD

More information

Medical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece

Medical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece Medical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece Disclosures Grants: ALARM investigator received research grants

More information

Circulatory Support: From IABP to LVAD

Circulatory Support: From IABP to LVAD Circulatory Support: From IABP to LVAD Howard A Cohen, MD, FACC, FSCAI Director Division of Cardiovascular Intervention Co Director Cardiovascular Interventional ti Laboratories Lenox Hill Heart & Vascular

More information

Biomarkers in cardiovascular disease. Felix J. Rogers, DO, FACOI April 29, 2018

Biomarkers in cardiovascular disease. Felix J. Rogers, DO, FACOI April 29, 2018 Biomarkers in cardiovascular disease Felix J. Rogers, DO, FACOI April 29, 2018 Biomarkers NIH: A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological

More information

I know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists

I know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists I know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists Alessandro Fucili (Ferrara, IT) Massimo F Piepoli (Piacenza, IT) Clinical Case: 82 year old woman

More information

High Risk PCI for Heart Failure

High Risk PCI for Heart Failure High Risk PCI for Heart Failure Ray Matthews MD Professor of Clinical Medicine Chief, Division of Cardiovascular Medicine University of Southern California Los Angeles, California Disclosures Abiomed Research

More information

Who is the high risk patient?

Who is the high risk patient? Who is the high risk patient? High risk of periprocedural death or other major complications (hemodynamic compromise, MI, stroke, dialysis) Contributors of Risk Lesion/Procedure Governed by 1. Patient

More information

Heart Failure. Disclosures. Objectives: 8/28/2017. This is not a virus. It doesn t go away. none

Heart Failure. Disclosures. Objectives: 8/28/2017. This is not a virus. It doesn t go away. none Heart Failure This is not a virus. It doesn t go away Shelley Wojtaszczyk, FNP-C, CHFN Heart Failure Program Coordinator Mercy Hospital of Buffalo none Disclosures Objectives: Defining and identifying

More information

Heart failure. Failure? blood supply insufficient for body needs. CHF = congestive heart failure. increased blood volume, interstitial fluid

Heart failure. Failure? blood supply insufficient for body needs. CHF = congestive heart failure. increased blood volume, interstitial fluid Failure? blood supply insufficient for body needs CHF = congestive heart failure increased blood volume, interstitial fluid Underlying causes/risk factors Ischemic heart disease (CAD) 70% hypertension

More information

Controversies in Cardiogenic Shock. Timothy D. Henry, MD Cedars-Sinai Heart Institute

Controversies in Cardiogenic Shock. Timothy D. Henry, MD Cedars-Sinai Heart Institute Controversies in Cardiogenic Shock Timothy D. Henry, MD Cedars-Sinai Heart Institute Key Issues Cardiac Arrest-Cardiogenic shock interaction New SCAI Classification Refractory Shock Shock with Multivessel

More information

Images have been removed from the PowerPoint slides in this handout due to copyright restrictions.

Images have been removed from the PowerPoint slides in this handout due to copyright restrictions. Heart Failure Heart Failure Introduction and History AHA 2015 Statistics About 6 million Americans 870,000 new cases each year 1 in 9 deaths related to HF Almost 1 million hospitalizations each year (cost

More information

Disclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17

Disclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17 Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies

More information

What s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine

What s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine What s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine Current Guideline of Treatment Asymptomatic Mild/Mod Severe Refractory Correct Cause: Arrhythmias

More information

Heart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)

Heart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea) Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types

More information

The Role of Mechanical Circulatory Support in Cardiogenic Shock: When to Utilize

The Role of Mechanical Circulatory Support in Cardiogenic Shock: When to Utilize The Role of Mechanical Circulatory Support in Cardiogenic Shock: Presented by Nancy Scroggins ACNP, CNS-CC CV Surgery ACNP Bayshore Medical Center The Role of Mechanical Circulatory Support in Cardiogenic

More information

Pharmacological Treatment for Chronic Heart Failure. Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014

Pharmacological Treatment for Chronic Heart Failure. Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014 Pharmacological Treatment for Chronic Heart Failure Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014 1 ACC/AHA 2005 guideline update for Diagnosis & management of CHF in the Adult -SA Hunt

More information

Outline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan

Outline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan New Pharmacological Therapies for Heart Failure Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center

More information

MANAGEMENT OF CARDIOGENIC SHOCK

MANAGEMENT OF CARDIOGENIC SHOCK MANAGEMENT OF CARDIOGENIC SHOCK CASE PRESENTATION 37 year old Dutch female No known coronary artery disease risk factors 1 week post partum at time of presentation (G3P3) after an uncomplicated normal

More information

Ejection Fraction in Patients With Chronic Heart Failure. Diastolic Heart Failure or Heart Failure with Preserved Ejection Fraction

Ejection Fraction in Patients With Chronic Heart Failure. Diastolic Heart Failure or Heart Failure with Preserved Ejection Fraction Diastolic Heart Failure or Heart Failure with Preserved Ejection Fraction Keith Miller MD Diastolic Heart Failure Risk Factors Common Risk Factors Aging Female gender Obesity Hypertension Diabetes mellitus

More information